Background COVID-19 vaccines have been recommended to people with multiple sclerosis
(pwMS) and, to ensure durable immunity, a third booster dose has been administered in …

An mRNA COVID-19 vaccine does not increase the short-term risk of relapses in people with
multiple sclerosis (MS), a new study indicates. Di Filippo et al. analysed data from 324 …

Background Data are sparse regarding the safety of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) vaccines in patients with multiple sclerosis (MS). Objective To …

Background and Objectives People with multiple sclerosis (MS) have an increased risk of
severe coronavirus infection due to their level of motor disability or exposure to certain …

Background: Since vaccination against coronavirus disease 2019 (COVID-19) became
available, risks related to vaccinating patients with multiple sclerosis (MS) need to be …

Background Concerns about vaccination increased among patients with multiple sclerosis
(MS) regarding side effects, efficacy, and disease exacerbation. Recently there were reports …

Discussion Sufficient data have been available to assure the safety of vaccination against
various diseases in MS patients [3, 4]. Now, facing an unexpected devastating pandemic …

Background and Objectives The effects of the SARS-CoV-2 vaccination and infection on
clinical outcomes, including relapse risk, have been insufficiently explored in people with …

Background As immunity against SARS-COV-2 wanes following first and second doses of
vaccination, a third dose is administered in several countries around the world. Similarly to …

Background and purpose We evaluated whether there was a difference in the occurrence of
relapses pre‐and post‐COVID‐19 vaccination in a nationwide cohort of Danish patients with …